Bahram Valamehr

2020

In 2020, Bahram Valamehr earned a total compensation of $2.5M as Chief Research and Development Officer at Fate Therapeutics, a 13% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$195,000
Option Awards$1,324,347
Salary$390,000
Stock Awards$549,750
Total$2,459,097

Valamehr received $1.3M in option awards, accounting for 54% of the total pay in 2020.

Valamehr also received $195K in non-equity incentive plan, $390K in salary and $549.8K in stock awards.

Rankings

In 2020, Bahram Valamehr's compensation ranked 4,624th out of 13,090 executives tracked by ExecPay. In other words, Valamehr earned more than 64.7% of executives.

ClassificationRankingPercentile
All
4,624
out of 13,090
65th
Division
Manufacturing
1,879
out of 5,621
67th
Major group
Chemicals And Allied Products
736
out of 2,254
67th
Industry group
Drugs
631
out of 1,954
68th
Industry
Biological Products, Except Diagnostic Substances
147
out of 411
64th
Source: SEC filing on April 21, 2021.

Valamehr's colleagues

We found four more compensation records of executives who worked with Bahram Valamehr at Fate Therapeutics in 2020.

2020

Edward Dulac

Fate Therapeutics

Chief Financial Officer

2020

J Wolchko

Fate Therapeutics

Chief Executive Officer

2020

Cindy Tahl

Fate Therapeutics

General Counsel

2020

Daniel Shoemaker

Fate Therapeutics

Chief Scientific Officer

News

In-depth

You may also like